Q2FY20 revenues grew 13.7% YoY to | 3366.6 crore (I-direct estimate: | 3579.8 crore) mainly due to consolidation of the craft portfolio in the wellness segment. US revenues grew 9.7% YoY to | 1448.4 crore (I-direct estimate: | 1432.1 crore). Domestic formulations grew 9.5% YoY to | 977.8 crore (I-direct estimate: | 955.7 crore). EBITDA margins contracted 464 bps to 18.6% (I-direct estimate: 21.9%), mainly on account of higher other expenditure. EBITDA de-grew 9.0% YoY to | 625.6 crore (I-direct estimate: | 784.0 crore). Adjusted PAT (excluding net impairment charges of | 209.9...